Kite Pharma Inc (KITE) : Regents Of The University Of California has sold out all of its stake in Kite Pharma Inc during the most recent quarter, according to the disclosure filed by the company on May 10, 2016 with the SEC. The investment management company has sold out 6,850 shares of Kite Pharma Inc which is valued at $292,084.
Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in KITE in the latest quarter, The investment management firm added 62,968 additional shares and now holds a total of 956,903 shares of Kite Pharma Inc which is valued at $40,802,344. Kite Pharma Inc makes up approx 0.01% of Blackrock Institutional Trust Company N.a.’s portfolio. Financial Architects Inc added KITE to its portfolio by purchasing 300 company shares during the most recent quarter which is valued at $12,792.Nationwide Fund Advisors boosted its stake in KITE in the latest quarter, The investment management firm added 9,213 additional shares and now holds a total of 32,702 shares of Kite Pharma Inc which is valued at $1,460,144. Kite Pharma Inc makes up approx 0.01% of Nationwide Fund Advisors’s portfolio.Smith Asset Management Group Lp reduced its stake in KITE by selling 80 shares or 1.12% in the most recent quarter. The Hedge Fund company now holds 7,050 shares of KITE which is valued at $314,783. Kite Pharma Inc makes up approx 0.01% of Smith Asset Management Group Lp’s portfolio.American Century Companies Inc boosted its stake in KITE in the latest quarter, The investment management firm added 14,270 additional shares and now holds a total of 285,536 shares of Kite Pharma Inc which is valued at $12,749,182. Kite Pharma Inc makes up approx 0.01% of American Century Companies Inc’s portfolio.
Kite Pharma Inc opened for trading at $43.08 and hit $45.25 on the upside on Monday, eventually ending the session at $45.04, with a gain of 5.63% or 2.4 points. The heightened volatility saw the trading volume jump to 7,49,204 shares. Company has a market cap of $2,213 M.
On the company’s financial health, Kite Pharma Inc reported $-0.60 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.73. The company had revenue of $5.10 million for the quarter, compared to analysts expectations of $4.61 million. The company’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.36 EPS.
Many Wall Street Analysts have commented on Kite Pharma Inc. Shares were Reiterated by Mizuho on May 10, 2016 to “Buy” and Lowered the Price Target to $ 80 from a previous price target of $90 .Citigroup Initiated Kite Pharma Inc on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $67.
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT) which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19 is a CAR-based therapy for the treatment of refractory diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR KTE-C19CAR and EGFRvlll CAR among others.